JP2021001224A - 身体的ストレスへの適応を強化するためのd−リボースの使用 - Google Patents
身体的ストレスへの適応を強化するためのd−リボースの使用 Download PDFInfo
- Publication number
- JP2021001224A JP2021001224A JP2020167906A JP2020167906A JP2021001224A JP 2021001224 A JP2021001224 A JP 2021001224A JP 2020167906 A JP2020167906 A JP 2020167906A JP 2020167906 A JP2020167906 A JP 2020167906A JP 2021001224 A JP2021001224 A JP 2021001224A
- Authority
- JP
- Japan
- Prior art keywords
- exercise
- treatment agent
- ribose
- dex
- physical exercise
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title claims abstract description 111
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 title claims abstract description 55
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 230000006978 adaptation Effects 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001301 oxygen Substances 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract 12
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 78
- 239000008121 dextrose Substances 0.000 description 37
- 102000004420 Creatine Kinase Human genes 0.000 description 13
- 108010042126 Creatine kinase Proteins 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000011888 snacks Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/33—High-energy foods and drinks, sports drinks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
対象は、健康な個体26人(女性10人、男性16人)であった。各対象は、補充投与のためにDR対象又はDEX対象としてランダムに分類された。さらに、各対象は、研究プロトコールの一部ではない追加の別個の運動セッションを何ら行わずに、通常の日常活動を行うだけでなく、研究中に彼又は彼女の通常の食事を維持することが求められた。
Unfitサブグループの平均年齢は27.7±3A年であり、Unfitサブグループの平均ピークVO2は39.9+4.1mL/kg/分であった。フィットサブグループは、4人の女性と9人の男性で構成されていた。フィットサブグループの平均年齢は27.6±3.5歳であり、フィットサブグループの平均ピークVO2は52.2+4.3mL/kg/分であった。
試験前(ベースライン)の評価
各対象が研究室に最初に訪れた際、対象は、最大の酸素摂取量及び血液乳酸塩評価を受け、サイクルエルゴメータを用いて2分間の出力テスト評価を実施した。最初にサイクルエルゴメータを使用して、各対象は、1キログラム(1kg)の抵抗で自己選択されたケイデンスで5分間のウォームアップ運動を完了した。サイクリング抵抗は、その後、4分間隔(0.5kg/4分)あたり0.5キログラムの割合で、意欲的な疲労まで増加させた。心拍数(HR)、酸素摂取量(VO2)及び乳酸血液サンプルを各段階の3分30秒(3’30’’)及び4分(4’)の時点で回収した。この評価は、その後の2回の処置セッション中に運動負荷を確立した。
各対象は、DR対象(DR補足の投与)又はDEX対象(DEX補給の投与)となるようにランダムに割り当てられた。対象に提供され、対象によって消費された補足とは別に、処置プロトコールは同一であった。特定の処置プロトコール(すなわち、補足及び運動セッションの投与)は、以下の表1に詳述される。
・運動開始の10分前;
・運動開始の20分後及び運動中;
・運動開始の40分後及び運動中;
・運動開始の60分後及び運動中;
・運動終了の24時間後(運動開始の25時間後)。
心拍数は、Polar HRモニターを用いて記録した。Bayerグルコースモニターを用いて血糖値を測定した。血液の乳酸濃度はAccuSport Lactate Analyzerで測定した。クレアチンキナーゼ及びBUNは、Abaxis Piccolo分析装置を用いて測定された。タイムトライアルパフォーマンス試験からの出力データは、スポーツ医学産業(SMI)ソフトウェアパッケージで評価した。
すべての表データをStatPac及びSPSS統計ソフトウェアを用いて、反復測定、時間及び処理を独立変数として用いた2−way ANOVAを用いて分析した。重大な相互作用が観察された場合、ターキー事後hoc検定を用いて手段を区別した。心拍数、RPE、血清乳酸塩レベル、血清CKレベル、血清BUNレベル及び測定された出力データは依存性尺度であった。有意性のアルファレベルはp<0.05に設定された。
全26人の対象は、有害事象なしに試験を完了した。DR対象及びDEX対象は、いずれもの主観的な苦情及び問題なしに、それぞれの補足を許容した。相互作用がないため、データは主効果として提示される。
Claims (5)
- 44mL/kg/分未満のピーク酸素摂取量(VO2max)を有するヒト対象の身体運動への適応を強化するための処置剤であって、該処置剤は、44mL/kg/分未満のVO2maxを有する前記ヒト対象による身体運動の期間前において、該ヒト対象への経口投与用に6〜10gのD−リボースを含有し、ならびに身体運動の期間内又は期間後において、該ヒト対象への経口投与用に6〜10gのD−リボースを含有するものであって、それにより該ヒト対象が身体運動への改善された適用を実証する、上記処置剤。
- 前記処置剤が、身体運動の期間の少なくとも2日前に経口投与されるものである、請求項1に記載の処置剤。
- 前記処置剤が、身体運動の期間前に1日2回の3〜5gのDリボース、及び身体運動の期間内又は身体運動の期間後に1日2回の3〜5gのDリボースを含む、請求項1又は2に記載の処置剤。
- 前記処置剤が、身体運動の期間前に3〜8時間の間隔で経口投与されるものである、請求項1〜3のいずれか1項に記載の処置剤。
- 前記処置剤が、身体運動の期間の少なくとも2時間前、及び身体運動の期間後の1時間以内に経口投与されるものである、請求項1〜4のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022178286A JP2022190163A (ja) | 2014-11-03 | 2022-11-07 | 身体的ストレスへの適応を強化するためのd-リボースの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074611P | 2014-11-03 | 2014-11-03 | |
US62/074,611 | 2014-11-03 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017524409A Division JP2017537079A (ja) | 2014-11-03 | 2015-11-03 | 身体的ストレスへの適応を強化するためのd−リボースの使用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022178286A Division JP2022190163A (ja) | 2014-11-03 | 2022-11-07 | 身体的ストレスへの適応を強化するためのd-リボースの使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021001224A true JP2021001224A (ja) | 2021-01-07 |
Family
ID=55909723
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017524409A Pending JP2017537079A (ja) | 2014-11-03 | 2015-11-03 | 身体的ストレスへの適応を強化するためのd−リボースの使用 |
JP2020167906A Pending JP2021001224A (ja) | 2014-11-03 | 2020-10-02 | 身体的ストレスへの適応を強化するためのd−リボースの使用 |
JP2022178286A Pending JP2022190163A (ja) | 2014-11-03 | 2022-11-07 | 身体的ストレスへの適応を強化するためのd-リボースの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017524409A Pending JP2017537079A (ja) | 2014-11-03 | 2015-11-03 | 身体的ストレスへの適応を強化するためのd−リボースの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022178286A Pending JP2022190163A (ja) | 2014-11-03 | 2022-11-07 | 身体的ストレスへの適応を強化するためのd-リボースの使用 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20170339984A1 (ja) |
EP (1) | EP3215162A4 (ja) |
JP (3) | JP2017537079A (ja) |
KR (1) | KR20170082568A (ja) |
CN (2) | CN107249597A (ja) |
AU (1) | AU2015343221B2 (ja) |
BR (1) | BR112017009302A2 (ja) |
CA (1) | CA2966628C (ja) |
HK (1) | HK1243944A1 (ja) |
RU (1) | RU2746128C2 (ja) |
WO (1) | WO2016073532A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107249597A (zh) * | 2014-11-03 | 2017-10-13 | 生物能量生命科学有限公司 | 使用d‑核糖增强对躯体应激的适应性 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11103797A (ja) * | 1997-07-22 | 1999-04-20 | Cerestar Holding Bv | 肉体運動を増強するための飲料 |
EP1095658A2 (en) * | 1999-10-27 | 2001-05-02 | Bioenergy Inc. | Use of ribose to treat fibromyalgia |
JP2002518321A (ja) * | 1998-06-19 | 2002-06-25 | バイオエナジー インコーポレイティド | エネルギーをインビボで増加させるための組成物 |
US20030212006A1 (en) * | 2002-05-13 | 2003-11-13 | Seifert John G. | Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals |
JP2010513279A (ja) * | 2006-12-15 | 2010-04-30 | バイオエナジー インコーポレイティド | 不十分な肺機能を処置するためのd−リボース |
JP2017537079A (ja) * | 2014-11-03 | 2017-12-14 | バイオエナジー ライフ サイエンス,インコーポレイティド | 身体的ストレスへの適応を強化するためのd−リボースの使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264093B (zh) * | 1998-06-19 | 2014-01-01 | 生物能量生命科学公司 | 用于增加体内能量的组合物 |
RU2169568C2 (ru) * | 1998-07-14 | 2001-06-27 | Омская государственная медицинская академия | Средство для коррекции энергетического обмена |
US6534480B2 (en) * | 1999-06-17 | 2003-03-18 | Bioenergy Inc. | Compositions for increasing energy in vivo |
CN105232564A (zh) * | 2008-08-20 | 2016-01-13 | 生物能生命科学公司 | D-核糖用于改善心肺功能的用途 |
-
2015
- 2015-11-03 CN CN201580072154.4A patent/CN107249597A/zh active Pending
- 2015-11-03 RU RU2017119010A patent/RU2746128C2/ru active
- 2015-11-03 KR KR1020177015125A patent/KR20170082568A/ko not_active Application Discontinuation
- 2015-11-03 BR BR112017009302A patent/BR112017009302A2/pt not_active Application Discontinuation
- 2015-11-03 CA CA2966628A patent/CA2966628C/en active Active
- 2015-11-03 EP EP15856774.3A patent/EP3215162A4/en active Pending
- 2015-11-03 JP JP2017524409A patent/JP2017537079A/ja active Pending
- 2015-11-03 CN CN202211336595.9A patent/CN115708831A/zh active Pending
- 2015-11-03 WO PCT/US2015/058902 patent/WO2016073532A1/en active Application Filing
- 2015-11-03 US US15/524,235 patent/US20170339984A1/en not_active Abandoned
- 2015-11-03 AU AU2015343221A patent/AU2015343221B2/en active Active
-
2018
- 2018-03-13 HK HK18103534.7A patent/HK1243944A1/zh unknown
-
2020
- 2020-10-02 JP JP2020167906A patent/JP2021001224A/ja active Pending
-
2021
- 2021-04-12 US US17/228,314 patent/US20210227854A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022178286A patent/JP2022190163A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11103797A (ja) * | 1997-07-22 | 1999-04-20 | Cerestar Holding Bv | 肉体運動を増強するための飲料 |
JP2002518321A (ja) * | 1998-06-19 | 2002-06-25 | バイオエナジー インコーポレイティド | エネルギーをインビボで増加させるための組成物 |
EP1095658A2 (en) * | 1999-10-27 | 2001-05-02 | Bioenergy Inc. | Use of ribose to treat fibromyalgia |
US20030212006A1 (en) * | 2002-05-13 | 2003-11-13 | Seifert John G. | Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals |
JP2010513279A (ja) * | 2006-12-15 | 2010-04-30 | バイオエナジー インコーポレイティド | 不十分な肺機能を処置するためのd−リボース |
JP2017537079A (ja) * | 2014-11-03 | 2017-12-14 | バイオエナジー ライフ サイエンス,インコーポレイティド | 身体的ストレスへの適応を強化するためのd−リボースの使用 |
Non-Patent Citations (3)
Title |
---|
INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM, vol. 15, JPN6019030121, 2005, pages 653 - 664, ISSN: 0004619720 * |
POLAR FT60 USER MANUAL, JPN6021041070, 2013, pages 7, ISSN: 0004980135 * |
日呼吸会誌, vol. 39, no. 4, JPN6020017509, 2001, pages 231 - 237, ISSN: 0004980136 * |
Also Published As
Publication number | Publication date |
---|---|
EP3215162A4 (en) | 2018-06-27 |
RU2017119010A (ru) | 2018-12-06 |
RU2017119010A3 (ja) | 2019-06-10 |
RU2746128C2 (ru) | 2021-04-07 |
CN115708831A (zh) | 2023-02-24 |
US20170339984A1 (en) | 2017-11-30 |
AU2015343221B2 (en) | 2021-04-08 |
CA2966628A1 (en) | 2016-05-12 |
HK1243944A1 (zh) | 2018-07-27 |
BR112017009302A2 (pt) | 2017-12-19 |
EP3215162A1 (en) | 2017-09-13 |
JP2017537079A (ja) | 2017-12-14 |
CA2966628C (en) | 2023-08-29 |
US20210227854A1 (en) | 2021-07-29 |
WO2016073532A1 (en) | 2016-05-12 |
CN107249597A (zh) | 2017-10-13 |
JP2022190163A (ja) | 2022-12-22 |
KR20170082568A (ko) | 2017-07-14 |
AU2015343221A1 (en) | 2017-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ransone et al. | The effect of β-hydroxy β-methylbutyrate on muscular strength and body composition in collegiate football players | |
Aedma et al. | Short-term creatine supplementation has no impact on upper-body anaerobic power in trained wrestlers | |
Tinsley et al. | Changes in body composition and neuromuscular performance through preparation, 2 competitions, and a recovery period in an experienced female physique athlete | |
Hackney et al. | Timing protein intake increases energy expenditure 24 h after resistance training | |
Lockwood et al. | Low-calorie energy drink improves physiological response to exercise in previously sedentary men: a placebo-controlled efficacy and safety study | |
Wax et al. | Effects of carbohydrate supplementation on force output and time to exhaustion during static leg contractions superimposed with electromyostimulation | |
Wax et al. | Effects of supplemental carbohydrate ingestion during superimposed electromyostimulation exercise in elite weightlifters | |
Marterer et al. | 6-week high-intensity interval training (HIIT) of the lower extremities improves VO2max of the upper extremities | |
Pihoker et al. | The effects of nutrient timing on training adaptations in resistance-trained females | |
Vissing et al. | Myocellular adaptations to low-load blood flow restricted resistance training | |
JP2022190163A (ja) | 身体的ストレスへの適応を強化するためのd-リボースの使用 | |
Amirsasan et al. | The effects of two different dosages of BCAA supplementation on a serum indicators of muscle damage in wrestlers | |
Kalytka et al. | Comparative analysis of functional capabilities and special working ability of men and women, specializing in 800 m and 1500 m running | |
Kang et al. | Acute effect of intensity fluctuation on energy output and substrate utilization | |
Feng et al. | Study on the effect of ketogenic diet combined with aerobic exercise on body posture, cardiopulmonary function and blood glucose of female college students | |
Bordonie | The effect of dietary nitrate supplementation on physical and cognitive performance during load carriage in military cadets | |
Prado et al. | Effect of a nutritional intervention associated with different models of physical training on health parameters of adult and elderly women: A Randomized Trial | |
Tun et al. | THE EFFECT OF HIGH-INTENSITY INTERVAL TRAINING, MODERATE-INTENSITY INTERVAL TRAINING, AND CONTINUOUS TRAINING ON ANAEROBIC AND AEROBIC CAPACITY | |
Miller | Six Weeks of Creatine-Electrolyte Supplement Effects on Muscle Fatigability | |
Dewhurst-Trigg | The Effect of Dietary Nitrate Supplementation on Agility, Linear Sprint and Vertical Jump Performance | |
Khong et al. | Effect of High and Low Carbohydrate Meals on Sustained Maximum Voluntary Contraction (MVC) after Prolonged Exercise | |
Madsen et al. | The Effects Of Recovery Time On Subsequent Maximal Resistance Training Performance In Trained Females: 1462 Board# 202 May 29, 9: 00 AM-10: 30 AM | |
Wells | The influence of L-arginine on vascular endothelial function at rest and during sympathetic activation | |
Chen et al. | Research article Arginine and antioxidant supplement on performance in elderly male cyclists: a randomized controlled trial | |
Suzuki et al. | Oral Administration Of BCAA Enhances Eccentric Training-Induced Adaptations In Rat Skeletal Muscle: 173 Board# 11 May 28, 9: 30 AM-11: 00 AM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201015 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220419 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221107 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221107 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20221122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221115 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221227 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230110 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230203 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20230207 |